Abstract
The purpose of this study was to prospectively analyze minimal residual disease(MRD) kinetics after reduced-intensity allogeneic stem cell transplantation (allo-SCT) in high-risk chronic lymphocytic leukemia (CLL). Subjects were the first 30 consecutive patients from a prospective clinical trial, and seven pilot patients treated identically. Using real-time quantitative-PCR (RQ-PCR) and/or flow-based MRD monitoring (sensitivity ⩾10−4), five distinct patterns of MRD kinetics could be identified: patients who promptly achieved durable MRD negativity without direct evidence of graft-versus-leukemia (GVL) effects (Group 1) (n=4; no clinical relapse); patients with complete and sustained MRD response after GVL induced by immunosuppression tapering (Group 2) or donor lymphocyte infusions (Group 3) (n=18; one relapse); patients without MRD response due to lack of GVL (Group 4) (n=2; two relapses); patients with incomplete and transient MRD response to GVL (Group 5) (n=4; three relapses). In summary, this study provides a comprehensive map of possible MRD courses and their prognostic implications after T-replete allo-SCT in high-risk CLL, indicating that effective GVL activity is induced virtually in all patients who develop chronic GVHD. However, in a significant proportion of cases, this does not translate into sustained disease control due to development of secondary GVL resistance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Brüggemann M, Pott C et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600–2602.
Moreno C, Villamor N, Esteve J, Colomer D, Bosch F, Campo E et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 4563–4569.
Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21: 12–17.
Ben Bassat I, Raanani P, Gale RP . Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplant 2007; 39: 441–446.
Khouri IF, Saliba RM, Admirand J, O’Brien S, Lee MS, Korbling M et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007; 137: 355–363.
Dreger P, Brand R, Milligan D, Corradini P, Finke J, Lambertenghi-Deliliers G et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005; 19: 1029–1033.
Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956–964.
Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410–1416.
Ritgen M, Lange A, Stilgenbauer S, Dohner H, Bretscher C, Bosse H et al. Unmutated immunoglobulin variable heavy chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003; 101: 2049–2053.
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.
Böttcher S, Ritgen M, Pott C, Brüggemann M, Raff T, Stilgenbauer S et al. Comparative analysis of minimal residual disease detection using four color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004; 18: 1637–1645.
Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29–35.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation-specific comrobidity index (HCT-CI): a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.
Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R . Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111: 446–452.
Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood 2005; 106: 4389–4396.
Sorror ML, Maris MB, Sandmaier BM, Storer B, Jain-Stuart M, Al-Ali H et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819–3829.
Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316–2323.
Huff CA, Matsui W, Smith BD, Jones RJ . The paradox of response and survival in cancer therapeutics. Blood 2006; 107: 431–434.
Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747–2753.
Delgado J, Thomson K, Russell N, Ewing J, Stewart W, Cook G et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation study. Blood 2006; 107: 1724–1730.
Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C et al. Predictors of Improved Progression-Free Survival After Nonmyeloablative Allogeneic Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia. Biol Blood Marrow Transplant 2006; 12: 1056–1064.
Acknowledgements
We thank the German CLL Study Group CLL3X investigators for their participation in this study; a complete list of investigators appears in ‘Appendix.’
This study was supported by grants from the Deutsche Jose-Carreras Leukämiestiftung e.V. Projects R02/18, R05/02 (MR, PD and MK).
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Presented in part in abstract form at the 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2005. Authorship: MR, PD and HD designed the trial; PD, SS, DB, JS, SC and NS were involved in patient care, sample and clinical data acquisition; MR, PD and MH were responsible for data management; SS and HD performed genetic analyses; MR, SB and MK performed MRD analyses; AH performed chimerism analyses; PD performed statistical analyses; MR and PD wrote the paper; and all authors checked the final version of the manuscript.
The authors declare that no potential conflict of interest exists.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Appendix
Appendix
CLL3X Investigators
Berlin, Charite Benjamin Franklin (Lutz Uharek); Essen, Universitätsklinikum (Dietrich Beelen); Göttingen, Universitätsklinikum (Bertram Glass); Hamburg, AK St Georg (Norbert Schmitz); Hannover, Medizinische Hochschule (Bernd Hertenstein, Michael Stadler, Matthias Eder); Heidelberg, Innere Medizin V (Peter Dreger, Manfred Hensel); Homburg, Universitätsklinikum (Jörg Schubert); Kiel, II. Medizinische Klinik (Martin Gramatzki); Köln, Universitätsklinikum (Michael Hallek); Marburg, Universitätsklinikum (Andreas Burchert); Montreal, Hopital Maisonneuve Rosemont (Sandra Cohen); Leipzig, Universitätsklinikum (Dietger Niederwieser); Regensburg, Universitätsklinikum (Ernst Holler); Ulm, III. Medizinische Klinik (Donald Bunjes, Stephan Stilgenbauer, Hartmut Döhner).
Rights and permissions
About this article
Cite this article
Ritgen, M., Böttcher, S., Stilgenbauer, S. et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 22, 1377–1386 (2008). https://doi.org/10.1038/leu.2008.96
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.96
Keywords
This article is cited by
-
Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation
Bone Marrow Transplantation (2020)
-
Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments
Leukemia (2018)
-
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses
Bone Marrow Transplantation (2017)
-
Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse
Bone Marrow Transplantation (2015)
-
Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality—a single institution experience
Annals of Hematology (2015)